Filing Details

Accession Number:
0001225208-15-017851
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-09-02 13:59:27
Reporting Period:
2015-08-31
Filing Date:
2015-09-02
Accepted Time:
2015-09-02 13:59:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
9892 Bard C R Inc BCR Surgical & Medical Instruments & Apparatus (3841) 221454160
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1204666 M Timothy Ring C/O C. R. Bard, Inc.
730 Central Avenue
Murray Hill NJ 07974
Chairman And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-08-03 16 $0.00 119,694 No 5 G Direct
Common Stock Acquisiton 2015-08-31 20,000 $88.76 139,694 No 4 M Direct
Common Stock Acquisiton 2015-08-31 20,000 $81.70 159,694 No 4 M Direct
Common Stock Disposition 2015-08-31 5,200 $197.00 154,494 No 4 S Direct
Common Stock Disposition 2015-08-31 6,917 $196.19 147,577 No 4 S Direct
Common Stock Disposition 2015-08-31 9,883 $195.24 137,694 No 4 S Direct
Common Stock Disposition 2015-08-31 18,000 $194.22 119,694 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (Right to Buy) Disposition 2015-08-31 20,000 $0.00 20,000 $88.76
Common Stock Option (Right to Buy) Disposition 2015-08-31 20,000 $0.00 20,000 $81.70
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
62,052 2018-07-09 No 4 M Direct
30,543 2019-12-09 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,591 Indirect 401(k) Plan
Common Stock 723 Indirect By Children
Footnotes
  1. Option exercise and sales are pursuant to a previously disclosed 10b5-1 plan.
  2. Represents the weighted average sales price for price increments ranging from $196.725 to $197.56. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
  3. Represents the weighted average sales price for price increments ranging from $195.715 to $196.69. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
  4. Represents the weighted average sales price for price increments ranging from $194.69 to $195.68. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
  5. Represents the weighted average sales price for price increments ranging from $193.685 to $194.68. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
  6. Includes 2.297 shares acquired under the Company's 401(k) Plan from May 9, 2015 to July 31, 2015.
  7. The reporting person disclaims beneficial ownership of the shares held by his children and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.
  8. Performance options granted under the 2003 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated). Also granted in tandem with these options are Limited Stock Appreciation Rights which can only be exercised upon a "Change of Control" as defined in the Plan.
  9. Options fully vested in accordance with schedule upon achievement of certain performance criteria.